Marie-Louise Vachon
Chercheuse associée
Axe Maladies infectieuses et immunitaires
Publications
View all-
article Nicolls S, Karlsen E, Martel-Laferrière V, Vachon ML, Yudin MH, Money D, McClymont E and
Rates of HPV Vaccination among Women and People with a Cervix Living with HIV in Canada
J Obstet Gynaecol Can 2026.
-
article Karlsen E, Langlois J, Boucoiran I, Brophy J, Elwood C, Hankins C, Hornsberger A, Krajden M, Lee M, Loutfy M, Martel-Laferrière V, Ogilvie GS, Poliquin V, Sadarangani M, Severini A, Singer J, Sivro A, Vachon ML, van Schalkwyk J, Walmsley S, Wong A, Yaphe S, Yudin MH, McClymont E, Money D
Rationale and design of a clinical trial of a reduced dosing schedule for the nonavalent human papillomavirus vaccine in women living with HIV: The NOVA-HIV study
Contemp Clin Trials 170 2026.
-
article Walmsley SL, Lovblom LE, Boyachuk B, Cooper C, Martel-Laferrière V, Loutfy M, Vachon ML, Haider S, Aldebes P, Colwill K, Gingras AC, Qi F, Klein MB
SARS-CoV-2 Infection and COVID-19 Vaccine Antibody Responses in Two Canadian Cohorts of Persons Living with HIV
Antibodies (Basel) 15 (2), 2026.
Projects
- A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living with HIV, from 2022-10-01 to 2027-09-30
- A Phase 2,Multicenter,Randomized,Double-Blind,Placebo-controlled Study to Evaluate Efficacy,Safety,Tolerability,and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral [...], from 2024-03-28 to 2029-12-25
- After the Cure: Measuring the full impacts of direct-acting antivirals for people living with HIV/hepatitis C virus coinfection in Canada, from 2023-04-01 to 2027-03-31
- Building Capacity in Innovative Adaptive Trial Designs for HIV and STBBI Research: The CTN-Québec Training Platform, from 2025-10-01 to 2029-09-30
- An Operationally Seamless Phase 2/3 Randomized, Open-label, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 ...Treatment-Naive People With HIV-1, from 2026-08-28 to 2031-12-25
- Surveillance des réponses immunitaires au vaccin contre la COVID-19 chez les personnes vivant avec le VIH-1, from 2021-12-01 to 2025-03-31